Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

On January 30, 2024, the Board of Directors (the "Board") of ARCA biopharma, Inc. (the "Company") approved paying compensation to its existing non-employee directors, pursuant to the Company's Director Compensation Policy, by granting each of Drs. Linda Grais, Anders Hove and Raymond Woosley, and Messrs. Robert Conway, Daniel Mitchell, Jacob Ma-Weaver and James Flynn options to purchase 6,000 shares of the Company's common stock (the "Options") at an exercise price of $1.64 per share, the closing price of the Company's common stock on The Nasdaq Global Market on January 30, 2024, rounded up to the nearest whole cent. The Options are subject to the terms and conditions of the ARCA 2020 Equity Incentive Plan (the "Plan") and the Company's standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The Options vest in 12 equal monthly installments beginning on January 30, 2024, assuming Drs. Grais', Hove's and Woosley's, and Messrs. Conway's, Mitchell's, Ma-Weaver's and Flynn's continued service on the Board for such periods.